The bottom line was up even more strongly with adjusted pre-tax profit increasing by 34% from GBP 22.7m in 2015 to “no less than” GBP 30.5m in 2016. One year in and the USD 70m bet on CTi is paying off.
RWS has completed the management handover from CTi’s previous owners and managers Mary and Ted Gawlicki to Sheena Dempsey, a Lionbridge veteran. Dempsey was hired as CTi’s CEO in late August 2015. Dempsey told Slator in September 2016 that RWS will keep the CTi brand and has folded its existing life sciences business PharmaQuest as well as its Medical Translation Division into CTi.
RWS’ online patent database service PatBase continued to post steady growth of 7%. The subscription-based offering represents less than 5% of RWS’ overall revenue, but enjoys higher margins than the service business.
Brexit’s Blessings
Brexit has been a blessing to RWS in the short-term. Over 80% of revenues are in non-sterling, and the currency’s recent plunge boosted results. RWS has also been busy paying down the USD 45m loan it took out to fund the CTi acquisition. Net debt as of September 30 stood at GBP 1.5m.
RWS’ strong finances positions it well for future acquisitions. The statement quotes RWS Chairman Andrew Brode as saying that they are “well placed to continue to selectively review a healthy pipeline of potential acquisitions.”
A long-term driver of RWS’ business was not mentioned in the statement. Europe’s Unitary Patent, which RWS previously admitted would not be a positive for the business, took another baby step towards implementation when the Netherlands became the eleventh country to ratify the Unified Patent Court (UPC) Agreement. However, some experts have speculated that the UK’s decision to leave the EU may delay the implementation of the UP.
